02 enero 2011

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information .

Authors: Soini, E. J. O.; Garca San Andrs, B.; Joensuu, T.

Source: Annals of Oncology, Volume 22, Number 1, 2011 , pp. 215-223(9)

Abstract:

Background: To assess the cost-effectiveness of trabectedin compared with end-stage treatment (EST) after failure with anthracycline and/or ifosfamide in metastatic soft tissue sarcoma (mSTS).

Design: Analysis was carried out using a probabilistic Markov model with trabectedin EST and EST arms, three health states (stable disease, progressive disease and death) and a lifetime perspective (3% annual discount rate). Finnish resources (drugs, mSTS, adverse events and travelling) and costs (year 2008) were used. Efficacy was based on an indirect comparison of the STS-201 and European Organisation for Research and Treatment of Cancer trials. QLQ-C30 scale scores were mapped to 15D, Short Form 6D and EuroQol 5D utilities. The outcome measures were the cost-effectiveness acceptability frontier, incremental cost per life year gained (LYG) and quality-adjusted life year (QALY) gained and the expected value of perfect information (EVPI).

Results: Trabectedin EST was associated with 14.0 (95% confidence interval 9.119.2) months longer survival, 36778 higher costs (32816 using hospital price for trabectedin) and 31590 (28192) incremental cost per LYG with an EVPI of 3008 (3188) compared with EST. With a threshold of 50000 per LYG, trabectedin EST had 98.5% (98.2%) probability of being cost-effective. The incremental cost per QALY gained with trabectedin EST was 4263347735 (3799242819) compared with EST. The results were relatively insensitive to changes.

Conclusion: Trabectedin is a potentially cost-effective treatment of mSTS patients.
Keywords: cancer; economic evaluation; leiomyosarcoma; liposarcoma; quality of life; trabectedin .

Publication date: 2011-01-01